StockData
Neuraxis, INC logo

Neuraxis, INC (NRXS) company profile

NRXSNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 0/30
$4.87+0.26 (+5.64%)

Close on Nov 18, 2026Market cap $61.16MP/E –Yield –

About Neuraxis

Electromedical & Electrotherapeutic Apparatus, SIC 3845

Neuraxis, Inc. is a medical technology company that develops neuromodulation therapies for chronic and debilitating conditions of the gastrointestinal digestive system caused by disorders of gut-brain interaction. Its primary offering is IB-Stim, a proprietary Percutaneous Electrical Nerve Field Stimulation medical device cleared by the FDA to treat functional abdominal pain associated with irritable bowel syndrome, functional dyspepsia, and related nausea symptoms in patients eight years of age and older. The company also offers the Rectal Expulsion Device, which evaluates rectal neuromuscular function and tests for rectal hypersensitivity in adults. Target customers include pediatric and adult patients treated by pediatricians, pediatric gastroenterologists, and trained healthcare providers in clinical settings.

The company operates in the United States and holds a Federal Supply Schedule contract with the federal government to supply its IB-Stim products. Neuraxis maintains its corporate headquarters and principal executive offices in Carmel, Indiana.

Summary of the business section of Neuraxis's latest annual report, written by StockData.

Company profile

Company

Legal name
Neuraxis, INC
Founded
2011
Headquarters
Carmel, IN
Address
11611 N. Meridian St, Suite 330 46032
Phone
(812) 689-0791
Employees
24, Dec 31, 2025
Industry
Electromedical & Electrotherapeutic Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Rosenberg Rich Baker Berman, P.A., Somerset, New Jersey

Stock & identifiers

Ticker
NRXS
Exchange
NYSE
IPO date
Aug 11, 2023
Shares outstanding
13M, Aug 6, 2026
Public float
$20.40M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1933567
CUSIP
64134X201
ISIN
US64134X2018
FIGI
BBG01C9N12C3
Share class FIGI
BBG01C9N1368
EIN
45-5079684

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Brian Allen CarricoChief Executive Officer, Director227,604
Thomas Joeseph CarricoCRO, CCO, CPO199,673
Timothy Robert HenrichsChief Financial Officer9,530
Craig Thomas BlanchardChief Commercial Officer–
Adrian MirandaCMO, SVP Science & Tech199,106
Kristin A. FergeDirector67,072
Gil AharonDirector628,181
Bradley Mitchell WatkinsDirector72,408
Jane Elizabeth KeyserDirector72,408

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$936.44K$1.32M$651.73K$72–
FY2024$578.38K$578.38K$460.08K$37–
FY2023$839.40K$839.40K$367.08K$42–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOtherTotalvs. prior year
Brian Carrico
Chief Executive Officer
$345.10K$180.96K$388.84K$21.54K$936.44K+62%
Timothy Henrichs
Chief Financial Officer
$327.34K$140.55K$327.92K$21.54K$817.35K+30%
Dr. Thomas Carrico
Chief Regulatory Officer
$300.00K$77.53K$166.31K$23.04K$566.88K+54%
Dr. Adrian Miranda
Chief Medical Officer
$300.00K$77.53K$171.90K$21.54K$570.97K+49%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 11, 2023
Offer price
$6.00
Securities offered
1,098,667
Gross proceeds
$6.59M
Exchange
NYSE American
First trading day
Aug 9, 2023
First-day close
$6.000.0%
Lock-up ends (est.)
Feb 5, 2024

“1,098,667 Shares of Common Stock 2,904,698 Shares of Common Stock held by Selling Stockholders We are offering 1,098,667 shares of common stock, par value $0.001 per share, of Neuraxis, Inc., at the initial public offering price of $6.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“of December 31, 2025, we had 24 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?